![]() ![]() ![]() PAF is a pioneer in the field of copayment support programs, providing more than $190 million in financial assistance to more than 95,000 patients who would have been otherwise unable to afford their pharmaceutical co-payments since 2004. Qualified patients whose applications are approved, are eligible for up to $3,000 per year in copayment assistance through the program. "We are grateful for the significant support we have received for the Hepatitis C silo which allows us to expand our Co-Pay Relief Program in such a meaningful way." The donation allows PAF to provide financial support to Hepatitis C patients ensuring their access to the treatments that can restore balance to their health and markedly improve their quality of life. It is in these cases that a patient's survival and overall health can be jeopardized if he or she is unable to access pharmaceutical treatment and therapies required to control the virus," said Alan Balch, PhD, CEO of PAF. "Management of Hepatitis C is extremely challenging for patients as most need ongoing medication to reduce their chance of liver damage or liver cancer. ![]() Supported through a generous donation of 5 million dollars, this CPR program silo providers financial support for pharmaceutical co-payments for insured patients who are facing financial distress and are unable to afford their costs associated with treatment for the virus. 5, 2014 /PRNewswire-USNewswire/ - Patient Advocate Foundation (PAF) announced today the expansion of its Co-Pay Relief (CPR) program with the opening of the Hepatitis C disease silo. The launch of the CPR Silo for Hepatitis C Patients Will Provide Financial Assistance to Patients in Need Simeprevir (Olysio) J & J Patient Access Programs Patient Advocate Foundation Announces Co-Pay Relief (CPR) Support for Patients Living with Hepatitis Cįrom Jules: both Gilead & J&J also have their own co-pay & Patient Assistance Programs: ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |